Skip to main content
Midas Edge

Tvardi Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

TVRD$1.41+47.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025

PART I –FINANCIAL INFORMATION

​​PAGENUMBER
​​​
Item 1.Cara Financial Statements (Unaudited):​
​​​
​Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 20241
​​​
​Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2025 and 20242
​​​
​Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2025 and 20243
​​​
​Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 20244
​​​
​Notes to Condensed Consolidated Financial Statements5
​​​
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations32
​​​
Item 3.Quantitative and Qualitative Disclosures About Market Risk47
​​​
Item 4.Controls and Procedures48
​​​
​PART II – OTHER INFORMATION​
​​​
Item 1.Legal Proceedings49
​​​
Item 1A.Risk Factors49
​​​
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds122
​​​
Item 3.Defaults Upon Senior Securities122
​​​
Item 4.Mine Safety Disclosures122
​​​
Item 5.Other Information122
​​​
Item 6.Exhibits123
​​​
​SIGNATURES125

PART I

FINANCIAL INFORMATION

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.